Acerand Therapeutics has reported updated findings from its first-in-human Phase I/II study of ACE-106 to treat advanced solid tumours.
Janux Therapeutics has announced the dosing of its first patient in a Phase I clinical trial evaluating JANX014 for mCRPC.
The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been ...
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less clinically meaningful than suggested. A review by Cochrane found that the ...
TG Therapeutics has completed enrolment in its Phase III trial investigating subcutaneous Briumvi in adults with RMS.
Precision BioSciences has received clinical trial application (CTA) approval to expand its global ELIMINATE-B study of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B.
GlycoNex has received Japan’s PMDA approval to commence a first-in-human Phase I clinical trial of GNX1021, its lead ADC candidate, for advanced gastrointestinal cancers.
CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab along with chemoimmunotherapy as a second-line treatment for patients with unresectable or ...
Rivus Pharmaceuticals has dosed the first patients in the AMPLIFY Phase II clinical trial evaluating HU6, an investigational oral therapy for MASH.
IDEAYA Biosciences and Servier have reported positive top line results from the Phase II/III registration trial, OptimUM-02, assessing darovasertib in combination with crizotinib for first-line ...
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.
The FDA has sent letters to more than 2,200 sponsors and investigators regarding the failure to publish trial data from more than 3,000 studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results